Table 3.
Studies Reporting Concentration of Drusen or Drusen-Related Risk in Central Macula Stratified by ETDRS Grid Subfields, Normalized by Subfield Area
| ETDRS Subfields | BDES* | BMES(10-y)† | BMES(15-y)† | HARBOR-MNV‡ | HARBOR-MA‡ | HARBOR-NP‡ |
|---|---|---|---|---|---|---|
| Center | 1.4 | 26.5 | 18.5 | 26.8 | 19.4 | 15.3 |
| Inner ring | 0.5 | 8.6 | 8.2 | 17.0 | 11.9 | 8.9 |
| Outer ring | 0.2 | 1.2 | 1.4 | 3.9 | 3.5 | 3.1 |
| Center/outer | 7.0 | 22.1 | 13.2 | 7.0 | 5.6 | 5.0 |
| Center/inner | 2.8 | 3.1 | 2.3 | 1.6 | 1.6 | 1.7 |
| Inner/outer | 2.5 | 7.2 | 5.9 | 4.4 | 3.4 | 2.9 |
BDES, Beaver Dam Eye Study, population-based, community-dwelling persons, 43 to 86 years, USA; soft indistinct drusen (% area) at baseline; color fundus photography.53
BMES, Blue Mountain Eye Study, population-based, community-dwelling persons, ≥ 49 years, Australia; 10- and 15-year incidence of neovascular or atrophic AMD stratified by drusen location at baseline, odds ratios for progression; color fundus photography.5,6
HARBOR, a study of ranibizumab administered monthly or on an as-needed basis in patients with sub-foveal neovascular age-related macular degeneration, fellow eyes to neovascular AMD (nvAMD) in a randomized clinical trial; drusen volume in 106 mm3 in eyes that progressed to macular neovascularization (MNV), macular atrophy (MA), or non-progressing (NP) as analyzed by Waldstein et al.55;55 OCT with Iowa Reference Algorithm.